The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...